Some Potential Merit Within MeiraGTx Holdings
MeiraGTx Holdings PLC MGTX
$11.79
▼ -1.59%
($-0.19)
🗓️ Earnings Next Week
Open
$11.90
Prev Close
$11.98
Day Range
$11.41 – $11.96
52W Range
$6.62 – $15.35
Market Cap
$1.09B
Beta
1.26
EPS (TTM)
$-1.49
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2018-06-08 |
| Shares Out. | 92,610,000 |
| Website | meiragtx.com/ ↗ |
| Phone | 16468607985 |
| Employees | 409 |
| Revenue | $293,000 |
| Gross Profit | $293,000 |
| Net Income | -$46.3M |
| Free Cash Flow | $4.2M |
| Total Assets | $244.7M |
| Total Liabilities | $302.8M |
| Equity | -$58.1M |
About MeiraGTx Holdings PLC
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
MeiraGTx Holdings PLC is a publicly traded company under the ticker symbol MGTX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
14 analysts (2026-07-01)